Helsinn Healthcare S A : Helsinn Group and BridgeBio Pharma s Affiliate QED Therapeutics Announce Health Canada Conditional Approval of TRUSELTIQ (infigratinib) for Patients with Cholangiocarcinoma finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Pivotal study demonstrated a clinically meaningful rate of tumor shrinkage (overall response rate) and duration of response in patients with previously-treated advanced cholangiocarcinoma (CCA) harboring